Nuclear factor-κB activation in primary lymphoma of bone

Virchows Archiv

Volumn 462, Issue 3, 2013, Pages 349-354

  Koens, Lianne ^a   Heyning, Fenna H ^b   Szepesi, Ágota ^c   Matolcsy, András ^c   Hogendoorn, Pancras C W ^a   Jansen, Patty M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

B cell lymphoma; Bone neoplasm; Nuclear factor B; Primary lymphoma of bone

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR REL;

ADULT; AGED; ARTICLE; BONE LYMPHOMA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; PRIORITY JOURNAL; STAINING; ADOLESCENT; BONE TUMOR; CANCER STAGING; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA; PATHOLOGY; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876083752     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1372-x     Document Type: Article

References (27)

1. Unni KK, Hogendoorn PC (2002) Malignant lymphoma. In: Fletcher CDM, Unni KK, Mertens F (eds) World Health Classification of tumours: Pathology amd genetics of tumours of soft tissue and bone. IARC Press, Lyon, pp 306-308
2. Lopez-Guillermo A, Colomo L, Jimenez M et al (2005) Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 23(12):2797-2804
3. Heyning FH, Kroon HM, Hogendoorn PC, Taminiau AH, van der Woude HJ (2007) MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance. Skeletal Radiol 36(10):937-944
4. Beal K, Allen L, Yahalom J (2006) Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 106(12):2652-2656
5. Heyning FH, Hogendoorn PC, Kramer MH et al (1999) Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 13(12):2094-2098
6. Heyning FH, Hogendoorn PC, Kramer MH, Holland CT, Dreef E, Jansen PM (2009) Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. J Clin Pathol 62(9):820-824
7. Adams H, Tzankov A, d'Hondt S, Jundt G, Dirnhofer S, Went P (2008) Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. Hum Pathol 39(9):1323-1330
8. de Leval L, Braaten KM, Ancukiewicz M, Kiggundu E, Delaney T, Mankin HJ, Harris NL (2003) Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 27(9):1269-1277
9. Bhagavathi S, Micale MA, Les K, Wilson JD, Wiggins ML, Fu K (2009) Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature. Am J Surg Pathol 33(10):1463-1469
10. Heyning FH, Jansen PM, Hogendoorn PC, Szuhai K (2010) Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. J Clin Pathol 63(12):1095-1100
11. Compagno M, Lim WK, Grunn A et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247):717-721
12. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861-1874
13. Ngo VN, Davis RE, Lamy L et al (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441(7089):106-110
14. Lam LT, Davis RE, Pierce J et al (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11(1):28-40
15. Harris NL (2008) Mature B-cell neoplasms. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organisation classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 179-267
16. Choi WW, Weisenburger DD, Greiner TC et al (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494-5502
17. Courts C, Montesinos-Rongen M, Martin-Subero JI et al (2007) Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 66(3):230-237
18. Curry CV, Ewton AA, Olsen RJ et al (2009) Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. J Hematop 2(1):20-26
19. Gupta M, Maurer MJ, Wellik LE et al (2012) Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 120(22):4400-4406
20. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275-282
21. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8(1):49-62
22. Sun SC, Ley SC (2008) New insights into NF-kappaB regulation and function. Trends Immunol 29(10):469-478
23. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33-40
24. Espinosa I, Briones J, Bordes R et al (2008) Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology 53(4):441-449
25. Bhagavathi S, Blenc AM, Amin M et al (2010) Primary cutaneous large B-cell lymphoma shows activation of nuclear factor kappa B and low incidence of Epstein-Barr virus. Am J Dermatopathol 32(5):439-441
26. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107(3):241-246
27. Dunleavy K, Pittaluga S, Czuczman MS (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113(24):6069-6076